Xenocor last week announced a strategic investment by Barvest Ventures’s Trudell Medical Group to increase the production of its single-use laparoscopic imaging system.

Trudell Medical’s chairperson George Baran will join Xenocor’s board of directors as part of the investment.

“Innovation has been critical for delivering solutions that improve quality of life and create positive economic outcomes. This has been our mission since our inception in 1922,” Baran said in a news release. “We feel our investment in Xenocor is a continuation of this tradition and see every reason for the Xenoscope to be successfully introduced into many markets around the world.”

Salt Lake City, Utah-based Xenocor’s Xenoscope laparoscopic imaging system is single-use, fog-free and portable with high-definition imaging. It has a single cord plug-and-play unit for easy integration and uses in multiple locations.

“Not only is Trudell Medical Group a global leader in its product categories, but they also manufacture adjunct products that complement our current offerings. This strategic investment alliance is a win-win partnership, which leaves the door open to additional innovation,” Xenocore CEO Evan Kelso said. “We feel fortunate to have George Baran on the board and such a commanding ally as we move this product into broader availability.”